1. Home
  2. VERU vs ANGH Comparison

VERU vs ANGH Comparison

Compare VERU & ANGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

SELL

Current Price

$2.09

Market Cap

41.9M

Sector

Health Care

ML Signal

SELL

Logo Anghami Inc.

ANGH

Anghami Inc.

SELL

Current Price

$3.36

Market Cap

33.8M

ML Signal

SELL

Company Overview

Basic Information
Metric
VERU
ANGH
Founded
1971
2012
Country
United States
United Arab Emirates
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
41.9M
33.8M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
VERU
ANGH
Price
$2.09
$3.36
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $25.67
N/A
AVG Volume (30 Days)
★ 106.8K
16.2K
Earning Date
12-16-2026
12-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $16,296,958.00
N/A
Revenue This Year
N/A
$251.30
Revenue Next Year
N/A
$26.67
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.04
$2.25
52 Week High
$7.33
$7.89

Technical Indicators

Market Signals
Indicator
VERU
ANGH
Relative Strength Index (RSI) 40.86 45.85
Support Level $2.09 $3.16
Resistance Level $2.68 $3.87
Average True Range (ATR) 0.11 0.14
MACD 0.00 -0.00
Stochastic Oscillator 26.67 39.02

Price Performance

Historical Comparison
VERU
ANGH

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About ANGH Anghami Inc.

Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. The Group's three reportable segments: Revenue from subscriptions, Revenue from advertisement, and Revenue from live events. It generates the majority of its revenue from subscriptions segment, which is comes from subscription fees. The advertisement revenue segment generated through the sale of advertising across the Group's content. Revenues from live events are generated from the sale of tickets, food and beverage & sponsorship. It derives maximum revenue from KSA.

Share on Social Networks: